The standard of care for elderly glioblastoma patients is 40Gy in 15 fraction radiotherapy with temozolomide (TMZ). However, this regimen has a lower biologic equivalent dose (BED) compared to the Stupp regimen of 60Gy in 30 fractions. We hypothesize that accelerated hypofractionated radiation of 52.5Gy in 15 fractions (BED equivalent to Stupp) will have superior survival compared to 40Gy in 15 fractions. Elderly patients (≥ 65years old) who received hypofractionated radiation with TMZ from 2010 to 2020 were included in this analysis. Overall survival (OS) and progression free survival were defined as the time elapsed between surgery/biopsy and death from any cause or progression. Baseline characteristics were compared between patients who received 40 and 52.5Gy. Univariable and multivariable analyses were performed. Sixty-six newly diagnosed patients were eligible for analysis. Thirty-nine patients were treated with 40Gy in 15 fractions while twenty-seven were treated with 52.5Gy in 15 fractions. Patients had no significant differences in age, sex, methylation status, or performance status. OS was superior in the 52.5Gy group (14.1months) when compared to the 40Gy group (7.9months, p = 0.011). Isoeffective dosing to 52.5Gy was shown to be an independent prognostic factor for improved OS on multivariable analysis. Isoeffective dosing to 52.5Gy in 15 fractions was associated with superior OS compared to standard of care 40Gy in 15 fractions. These hypothesis generating data support accelerated hypofractionation in future prospective trials.